GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » FCF Yield %

Allakos (Allakos) FCF Yield % : -129.63 (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allakos FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Allakos's Trailing 12-Month Free Cash Flow is $-117.07 Mil, and Market Cap is $90.32 Mil. Therefore, Allakos's FCF Yield % for today is -129.63%.

The historical rank and industry rank for Allakos's FCF Yield % or its related term are showing as below:

ALLK' s FCF Yield % Range Over the Past 10 Years
Min: -156.81   Med: 0   Max: 0
Current: -129.63


ALLK's FCF Yield % is ranked worse than
87.1% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs ALLK: -129.63

Allakos's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Allakos FCF Yield % Historical Data

The historical data trend for Allakos's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos FCF Yield % Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial -1.37 -1.54 -45.08 -40.10 -48.87

Allakos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.19 -31.57 -34.71 -59.60 -40.46

Competitive Comparison of Allakos's FCF Yield %

For the Biotechnology subindustry, Allakos's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allakos's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allakos's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Allakos's FCF Yield % falls into.



Allakos FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Allakos's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-117.072 / 239.5575
=-48.87%

Allakos's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-24.234 * 4 / 239.5575
=-40.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allakos FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Allakos FCF Yield % Related Terms

Thank you for viewing the detailed overview of Allakos's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allakos (Allakos) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Executives
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Amy L Ladd director INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson officer: Chief Medical Officer ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald officer: General Counsel and Secretary ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi officer: COO, CFO and Secretary ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander director, officer: President and CEO 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Harlan Baird Radford officer: Chief Financial Officer C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Rasmussen Henrik S Md officer: Chief Medical Officer 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn director, 10 percent owner 5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson 10 percent owner 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067